Oxford Asset Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Oxford Asset Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-80,262	Closed	-$67K	–	2280
2019 Q3	$67K	Sell	80,262 -47,340	-37%	-$36.1K	﹤0.01%	1644
2019 Q2	$110K	Buy	127,602 +22,217	+21%	+$20.5K	﹤0.01%	1605
2019 Q1	$102K	Sell	105,385 -246,495	-70%	-$260K	﹤0.01%	1568
2018 Q4	$258K	Sell	351,880 -81,122	-19%	-$133K	0.01%	1455
2018 Q3	$928K	Buy	433,002 +155,996	+56%	+$386K	0.02%	1040
2018 Q2	$1.45M	Buy	277,006 +35,147	+15%	+$154K	0.03%	852
2018 Q1	$943K	Buy	241,859 +58,558	+32%	+$206K	0.02%	968
2017 Q4	$490K	Buy	183,301 +132,090	+258%	+$387K	0.01%	1185
2017 Q3	$164K	Buy	+51,211	New	+$171K	﹤0.01%	1444
2016 Q4	–	Sell	-4,944	Closed	-$19K	–	968
2016 Q3	$19K	Sell	4,944 -3,286	-40%	-$12K	﹤0.01%	761
2016 Q2	$28K	Buy	+8,230	New	+$37.8K	﹤0.01%	774
2015 Q4	–	Sell	-1,047	Closed	-$15K	–	1058
2015 Q3	$15K	Sell	1,047 -120,376	-99%	-$2.08M	﹤0.01%	619
2015 Q2	$2.37M	Buy	121,423 +51,166	+73%	+$988K	0.06%	324
2015 Q1	$1.27M	Buy	+70,257	New	+$1.58M	0.03%	423
2014 Q3	–	Sell	-30,865	Closed	-$871K	–	867
2014 Q2	$871K	Sell	30,865 -112,057	-78%	-$3.37M	0.03%	510
2014 Q1	$4.86M	Sell	142,922 -28,464	-17%	-$973K	0.14%	228
2013 Q4	$3.29M	Buy	+171,386	New	+$3.12M	0.08%	327
2013 Q3	–	Sell	-3,384	Closed	-$36K	–	1050
2013 Q2	$36K	Buy	+3,384	New	+$39.7K	﹤0.01%	854

Other funds holding CTIC

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Oxford Asset Management's CTIC Position: Q4 2019 in Review

Oxford Asset Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2019, closing a stake of 80,262 shares — an estimated $67K sold.

Oxford Asset Management first reported a position in CTIC in Q2 2013 and held it in 18 quarters. The position peaked at $4.86M in Q1 2014. 40 funds tracked by Wall St. Rank hold CTIC as of Q4 2019.

Oxford Asset Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2019 after selling out during the quarter.
Oxford Asset Management sold 80,262 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2019, an estimated $67K.
Oxford Asset Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 18 quarters.
Oxford Asset Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $4.86M in Q1 2014.
40 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.